EWP
CYCN icon

Elevation Wealth Partners’s Cyclerion Therapeutics CYCN Stock Holding History

Elevation Wealth Partners’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$50 – 492
2025
Q1 		$50 Hold
20
– – ﹤0.01% 477
2024
Q4 		$65 Buy
+20
New +$56 ﹤0.01% 482

Other funds holding CYCN

TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Elevation Wealth Partners's CYCN Position: Q2 2025 in Review

Elevation Wealth Partners sold out of Cyclerion Therapeutics (CYCN) in Q2 2025, closing a stake of 20 shares — an estimated $50 sold.

Elevation Wealth Partners first reported a position in CYCN in Q4 2024 and held it in 2 quarters. The position peaked at $65 in Q4 2024. 17 funds tracked by Wall St. Rank hold CYCN as of Q2 2025.

  • Elevation Wealth Partners reported no remaining Cyclerion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Elevation Wealth Partners sold 20 Cyclerion Therapeutics shares in Q2 2025, an estimated $50.
  • Elevation Wealth Partners first reported a position in Cyclerion Therapeutics in Q4 2024 and held it in 2 quarters.
  • Elevation Wealth Partners's Cyclerion Therapeutics position peaked at $65 in Q4 2024.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2025.

Based on Elevation Wealth Partners's 13F filing for Q2 2025, filed 8 Jul 2025.